SCHEMBL7128046

SCHEMBL7128046

N=C(Nc1cc(Cl)cc(Nc2nc3ccc(Cl)cc3s2)c1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 4/20 0.47
SENP8 Q96LD8 4/20 0.47
SENP7 Q9BQF6 4/20 0.47
SENP6 Q9GZR1 4/20 0.47
DYRK1A Q13627 1/20 0.47
FSCN1 Q16658 1/20 0.47
NPC1 O15118 6/20 0.46
RAB9A P51151 6/20 0.46
MAPT P10636 5/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
ALOX12 P18054 1/20 0.46
HTT P42858 1/20 0.46
ACP1 P24666 1/20 0.45
CLK1 P49759 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22468024 0.75 DYRK1A (0.65) CASP3SENP8SENP7SENP6DYRK1A
SCHEMBL7119164 0.74 NPC1 (0.60) CASP3SENP8SENP7SENP6DYRK1A
SCHEMBL7125157 0.74 CCNA2 (0.35) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL1180003 0.72 DYRK1A (0.58) CASP3SENP8SENP7SENP6DYRK1A
SCHEMBL5025802 0.72 NPC1 (0.68) CASP3SENP8SENP7SENP6NPC1
SCHEMBL3217871 0.70 RAB9A (0.68) CASP3SENP8SENP7SENP6DYRK1A
SCHEMBL1176219 0.69 NPC1 (0.59) CASP3SENP8SENP7SENP6DYRK1A
SCHEMBL14433291 0.69 MAPT (0.55) CASP3SENP8SENP7SENP6DYRK1A
SCHEMBL8122841 0.69 SMN1; SMN2 (0.66) CASP3SENP8SENP7SENP6NPC1
SCHEMBL27004484 0.68 DYRK1A (0.62) CASP3SENP8SENP7SENP6DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 CASP3 2654/4885SENP8 2965/4885SENP7 3494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.